In a preclinic mouse model with multiple cancer cell lines including melanoma, DeAlmeida and Colleagues demonstrated that therapy with anti-VEGFA targeting agent induces the HIF1α-mediated activation of intratumoral CD8+ cells resulting in an increase in IFNγ and TNFα production (57). The gene discussed is VEGFA; the disease is cancer.